<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066234</url>
  </required_header>
  <id_info>
    <org_study_id>2009-04-004</org_study_id>
    <nct_id>NCT01066234</nct_id>
  </id_info>
  <brief_title>Adjuvant CCRT vs CT in Minimal N2 NSCLC</brief_title>
  <official_title>A Randomized Phase II Study of Adjuvant Concurrent Chemoradiotherapy vs Chemotherapy Alone in Completely Resected Microscopic N2 Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study propose adjuvant concurrent chemoradiotherapy vs chemotherapy alone in completely&#xD;
      resected microscopic N2 NSCLC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 15% of patients with non-small cell lung cancer are diagnosed with stage&#xD;
      IIIA-N2 disease. However, this subgroup is heterogeneous, with lymph nodes that are only&#xD;
      microscopically invaded to those that are radiologically visible with bulky ipsilateral&#xD;
      mediastinal lymph node involvement. Surgical resection in selected patients results in 5-year&#xD;
      survival rates of 7-24%.&#xD;
&#xD;
      The standard treatment for locally advanced clinical N2 disease is definitive concurrent&#xD;
      chemoradiotherapy or induction chemotherapy (± radiation) followed by operation. However, in&#xD;
      some patients, N2 status could be confirmed only after curative operation without any&#xD;
      evidence of N2 diseases through preoperative evaluation methods (CT, PET, mediastinoscopy).&#xD;
      We usually define those N2 disease found only after curative operation as microscopic N2, and&#xD;
      do adjuvant chemotherapy, radiotherapy or concurrent chemoradiotherapy. However, little data&#xD;
      about the adjuvant therapy for completely resected N2 disease have been available, Hence, we&#xD;
      propose a randomized phase II study of adjuvant concurrent chemoradiotherapy vs chemotherapy&#xD;
      alone in completely resected microscopic N2 NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Actual">January 18, 2021</completion_date>
  <primary_completion_date type="Actual">January 18, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of relapse</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>concurrent chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>concurrent chemoradiotherapy</intervention_name>
    <description>weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.</description>
    <arm_group_label>concurrent chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy only</intervention_name>
    <description>four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).</description>
    <arm_group_label>chemotherapy only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of stage IIIA(N2) NSCLC that was completely&#xD;
             resected by lobectomy, bilobectomy, pneumonectomy, or sleeve lobectomy through any&#xD;
             incision (thoracoscopic or video-assisted thorascopic surgery approaches were&#xD;
             acceptable)&#xD;
&#xD;
          2. &quot;Pathologic N2&quot; disease (involvement of N2 nodes can only be determined at the time of&#xD;
             surgical exploration or postoperative pathologic analysis)&#xD;
&#xD;
          3. Age ≥18years&#xD;
&#xD;
          4. No known residual disease (negative resection margin and no extracapsular invasion of&#xD;
             lymph node metastasis)&#xD;
&#xD;
          5. ECOG performance status of 0 to 1&#xD;
&#xD;
          6. No previous chemotherapy or RT&#xD;
&#xD;
          7. Adequate organ function as evidenced by the following; Absolute neutrophil count &gt; 1.5&#xD;
             x 109/L; platelets &gt; 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or ALT &lt; 5 UNL;&#xD;
             creatinine clearance ≥ 50mL/min&#xD;
&#xD;
          8. Written informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with preoperative mediastinoscopic N2 positive disease&#xD;
&#xD;
          2. Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or&#xD;
             arrhythmia&#xD;
&#xD;
          3. Patients with post-obstructive pneumonia or uncontrolled serious infection&#xD;
&#xD;
          4. Pregnant or nursing women ( Women of reproductive potential have to agree to use an&#xD;
             effective contraceptive method)&#xD;
&#xD;
          5. Prior history of malignancy within 5 years from study entry except for a adequately&#xD;
             treated basal cell or squamous cell skin cancer or in situ cervical cancer,&#xD;
             well-treated thyroid cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keunchil Park, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Keunchil Park</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Microscopic N2 Non-small Cell Lung Cancer</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

